MBX Biosciences (NASDAQ:MBX) Shares Gap Up – Still a Buy?

MBX Biosciences, Inc. (NASDAQ:MBX)’s share price gapped up before the market opened on Friday. The stock had previously closed at $56.55, but opened at $59.28. MBX Biosciences shares last traded at $59.7250, with a volume of 59,280 shares.

Analysts Set New Price Targets

Several research analysts have commented on the company. Wall Street Zen lowered MBX Biosciences from a “hold” rating to a “sell” rating in a research report on Saturday, August 8th. Guggenheim upped their target price on MBX Biosciences from $88.00 to $150.00 and gave the stock a “buy” rating in a research report on Friday. UBS Group reiterated a “buy” rating on shares of MBX Biosciences in a research note on Monday. Mizuho raised their target price on MBX Biosciences from $57.00 to $91.00 and gave the company an “outperform” rating in a report on Wednesday, July 29th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of MBX Biosciences in a research report on Friday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and two have given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $83.89.

MBX Biosciences Stock Performance

The company has a market cap of $2.83 billion, a P/E ratio of -24.34 and a beta of 0.10. The business has a fifty day simple moving average of $63.25 and a 200 day simple moving average of $47.47.

MBX Biosciences (NASDAQ:MBX) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.78) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.10). Equities research analysts expect that MBX Biosciences, Inc. will post -3.1 EPS for the current year.

Institutional Investors Weigh In On MBX Biosciences

A number of institutional investors have recently modified their holdings of the business. Wellington Management Group LLP grew its stake in MBX Biosciences by 55.9% during the 2nd quarter. Wellington Management Group LLP now owns 4,977,523 shares of the company’s stock worth $274,759,000 after buying an additional 1,785,699 shares during the last quarter. BlackRock Inc. acquired a new position in shares of MBX Biosciences during the second quarter valued at $183,467,000. Parkman Healthcare Partners LLC bought a new position in shares of MBX Biosciences during the second quarter worth about $44,170,000. Aaron Wealth Advisors LLC grew its position in shares of MBX Biosciences by 1,568.8% during the first quarter. Aaron Wealth Advisors LLC now owns 1,168,176 shares of the company’s stock worth $34,870,000 after acquiring an additional 1,098,176 shares during the last quarter. Finally, Eventide Asset Management LLC acquired a new stake in shares of MBX Biosciences in the 4th quarter worth about $28,071,000.

About MBX Biosciences

MBX Biosciences, Inc is a clinical-stage biopharmaceutical company focused on developing peptide therapies for endocrine and metabolic disorders. The company uses its Precision Endocrine Peptide platform to design engineered peptides intended to provide targeted activity, extended duration and more consistent treatment effects.

MBX’s lead program, MBX 1416, is an investigational long-acting parathyroid hormone receptor agonist being developed as a potential replacement therapy for people with hypoparathyroidism, a disorder in which the body produces insufficient parathyroid hormone.